 Benitec Biopharma, Inc. NASDAQ: BNTC, a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ddRNAi platform, today announced the initiation of the BB-301 Tissue Transduction Study in large animal subjects. 